Pharma Focus Europe

Biocina Secures Exclusive Contract Development and Manufacturing Organization (CDMO) Rights for Cellutx’s Innovative Minicircle DNA Technology Platform

Tuesday, June 04, 2024

BioCina Pty Ltd, a leading global biopharmaceutical contract development and manufacturing organization (CDMO), has obtained exclusive rights to use CelluTx's recombination-based plasmid system (RBPS) technology with its customers. RBPS is an advanced method for producing minicircle DNA (mcDNA) through site-specific recombination in a bacterial host, which separates the gene-containing minicircle from the rest of the plasmid, including antibiotic resistance genes and replication origins.

This technology offers several advantages over traditional mcDNA production methods, including scalability, exceptionally high recombination efficiency, higher yields, and simpler purification processes. The clear separation of minicircles from miniplasmids also allows for the production of larger minicircles that can accommodate complex gene cassettes. The streamlined structure of mcDNA results in enhanced and prolonged transgene expression, making it less immunogenic and safer for in vivo use. These benefits make RBPS a promising approach for advancing mcDNA production and broadening its applications in cell and gene therapies, as well as other innovative therapeutics.

One significant application of this technology is BioCina's cGMP program for GenomeFrontier, which utilizes RBPS to scale up GenomeFrontier's CAR-T product.

BioCina, commented, "We are excited to partner with CelluTx to offer this cutting-edge technology exclusively to our customers worldwide. We have already seen great success with this technology in our customer portfolio and look forward to advancing many more programs."

Maurits Geerlings, CEO of CelluTx, said, "We are very pleased to collaborate with BioCina to deploy RBPS minicircle DNA technology globally. BioCina's proven capabilities and strong customer commitment were crucial factors in our decision to partner with them."

Womack also highlighted Australia's appeal for biologics companies, noting, "Australia offers one of the most attractive tax incentives in the world, with up to a 48.5% cash rebate, making it an ideal location for scaling up and manufacturing biologics products."

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva